Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo

Aims  To investigate the role of basal nitric oxide (NO) production in regulating large artery stiffness in vivo. Methods  Incremental doses of the NO synthase inhibitor L‐NG‐monomethyl arginine (LNMMA: 0.1, 0.3, 1.0 and 3.0 mg kg−1 min−1) or placebo were infused in eight healthy men. Arterial stiff...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of clinical pharmacology Vol. 53; no. 2; pp. 189 - 192
Main Authors Wilkinson, Ian B., MacCallum, Helen, Cockcroft, John R., Webb, David J.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science, Ltd 01.02.2002
Blackwell Science
Subjects
Online AccessGet full text
ISSN0306-5251
1365-2125
DOI10.1046/j.1365-2125.2002.1528adoc.x

Cover

Loading…
More Information
Summary:Aims  To investigate the role of basal nitric oxide (NO) production in regulating large artery stiffness in vivo. Methods  Incremental doses of the NO synthase inhibitor L‐NG‐monomethyl arginine (LNMMA: 0.1, 0.3, 1.0 and 3.0 mg kg−1 min−1) or placebo were infused in eight healthy men. Arterial stiffness was assessed noninvasively by pulse wave analysis. Results  Compared with placebo, infusion of LNMMA led to a dose‐dependent increase in mean arterial pressure, peripheral vascular resistance, and aortic and systemic arterial stiffness. There was an accompanying reduction in heart rate and cardiac index. The highest dose of LNMMA resulted in an increase of 25% in AIx (95% confidence limits; 12, 38) and of 16 mmHg in mean arterial pressure (9, 23) compared with infusion of saline. Conclusions  These data indicate functional regulation of large artery stiffness in vivo by NO, and may provide new therapeutic strategies for cardiovascular risk reduction.
Bibliography:Present address: Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
Present Address: Dr Ian B. Wilkinson, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.
ISSN:0306-5251
1365-2125
DOI:10.1046/j.1365-2125.2002.1528adoc.x